Early doxorubicin cardiotoxicity in Malawian children admitted to Queen Elizabeth Central Hospital, Malawi. Issue 7 (15th March 2021)

• Record Type: Journal Article
• Authors: Moyo, Dominic; Chimalizeni, Yamikani; Chagaluka, George; Banda, Clifford G.; Molyneux, Elizabeth M.
• Is Part Of: Pediatric blood & cancer. Volume 68:Issue 7(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-03-15
• Subjects: cardiotoxicity -- children -- doxorubicin -- Malawi; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.29003
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract: Background: Doxorubicin is known to cause chemotherapy‐induced cardiotoxicity. In resource‐poor settings, monitoring for cardiotoxicity is not routinely done, and its incidence is unknown. The aim of this study was to determine the proportion of children who developed doxorubicin‐induced cardiotoxicity within 1 year of having received treatment at paediatric oncology ward. Methods: Children aged 3 months to 18 years with cancer were prospectively enrolled and followed up between January 2016 to June 2019. Transthoracic echocardiogram was done at baseline, 1 month, 6 months and a year after completion of therapy. Cardiotoxicity was defined as a decline in left ventricular ejection fraction (LVEF) of ≥10% to a final value of <50%. An overall incidence risk of developing cardiotoxicity was estimated. A one‐way analysis of variance (ANOVA) was conducted to compare baseline LVEF with follow‐up measurements. Findings: Ninety‐one children were enrolled, 74% (68/91) were male, and 67% (62/91) were aged 5 months to 14 years. Most patients received a doxorubicin cumulative dose between 100 and 200 mg/m 2 and no cardiotoxicity was observed during the study period. However, of 77 children with at least one follow up, five children 6.54% (95% CI: 2.1–14.5) experienced LVEF reduction of >10%, though not to a final value of <50%. No deterioration of systolic function was found among 20 children who completed follow‐up ( F = 2.43, p ‐value = .07). Interpretation: In this cohort of patients, most received a low cumulative doxorubicin dose and only 22% were available for evaluation at study end; no cardiotoxic events associated with doxorubicin administration were observed after 12 months.